Cancer Research Meeting Calendar Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 1400-1403, April 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by El-Bayoumy, K.
Right arrow Articles by Wynder, E. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by El-Bayoumy, K.
Right arrow Articles by Wynder, E. L.
[Cancer Research 59, 1400-1403, April 1, 1999]
© 1999 American Association for Cancer Research

Advances in Brief

Increased Expression of Cyclooxygenase-2 in Rat Lung Tumors Induced by the Tobacco-specific Nitrosamine 4-(Methylnitrosamino)-4-(3-pyridyl)-1-butanone

The Impact of a High-Fat Diet1

Karam El-Bayoumy2, Michael Iatropoulos, Shantu Amin, Dietrich Hoffmann and Ernst L. Wynder

American Health Foundation, Valhalla, New York 10595


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results and Discussion
 REFERENCES
 
Aberrant or excessive expression of cyclooxygenase (COX)-2 has been implicated in the pathogenesis of many disease processes, including carcinogenesis. COX-2 expression was immunohistochemically examined in archival samples (D. Hoffmann et al., Cancer Res., 53: 2758–2761, 1993) of lung neoplasms (adenomas, adenocarcinomas, and adenosquamous carcinomas) induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in male F344 rats that had been fed either a semipurified AIN-76A diet with high-fat (HF; 23.5% corn oil) or low-fat (LF; 5% corn oil) content. The intensity and extent of COX-2 positivity was graded from 0 (undetectable or negligible expression) to grades 1 (<30% expression), 2 (30–60% expression), 3 (60–90% expression), and 4 (>90% expression). The scoring criteria were similar to those used with specimens from human lung cancers (T. Hida et al., Cancer Res., 58: 3761–3764, 1998). In group 1 (NNK plus HF diet), adenomas, adenocarcinomas, and adenosquamous carcinomas were of mean grades 2, 3, and 4, respectively; in group 2 (NNK plus LF diet), the corresponding mean grades were 1, 1, and 3. Although control rats, given HF (group 3) or LF (group 4) diets but no NNK, developed spontaneous lung tumors, the expression of COX-2 was either negligible (one adenoma of grade 0 in group 3) or of a very low grade (one adenocarcinoma of grade 1 in group 4). In addition, the latency of the tumors in the peripheral lung in assays with NNK is significantly shorter in rats maintained on the HF diet than in those on LF diet. COX-2 expression was not evident in normal lung tissues. We report here for the first time that NNK induces increasingly higher levels of COX-2 expression with progressive stages of lung tumorigenesis when rats are fed the HF diet. The increase in COX-2 expression may be associated with the development of lung tumors induced by NNK. This well-defined animal model is valuable for studying modulation of COX-2 expression in lung carcinogenesis by various factors, including dietary components.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results and Discussion
 REFERENCES
 
Smoking of cigarettes, cigars, and pipes is causally related to the risk for cancer of the lung (1) . In recent decades, the rate of adenocarcinoma has been increasing relative to that of the formerly common tumor type, the squamous cell carcinoma (2, 3, 4) . This may reflect changes in cigarette formulation toward lower nicotine yields, which have led smokers to modify their smoking pattern, i.e., taking larger puff volumes while inhaling the smoke more deeply, which enables these carcinogens to reach the peripheral parts of the lung where the adenocarcinoma primarily develops (5) . Moreover, changes in cigarette make-up have also led to relatively higher smoke yields of the type of nicotine-derived carcinogenic N-nitrosamines that induce adenocarcinoma in laboratory animals (6) .

Tobacco-specific nitrosamines represent a class of potent animal lung carcinogens (7 , 8) . NNK3 (Fig. 1)Citation is a representative agent of this class. An etiological role of NNK in the causation of human lung cancer is supported by assays showing that human lung tissues can activate NNK to DNA-damaging agents (9) and that the lung is a target organ for NNK-induced carcinogenesis in rodents (reviewed in Ref. 10 ). NNK induces adenocarcinoma of the lung in mice, rats, and Syrian golden hamsters, independent of the route of administration (reviewed in Ref. 11 ).



View larger version (7K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Chemical structure of NNK.

 
The bioactivation of NNK in rats, mice, Patas monkeys, and several in vitro systems is catalyzed by multiple forms of cytochrome P450 isozymes (10) . However, Smith et al. (12) suggested that P450 enzymes are only partially responsible for the activation of NNK in human lung microsomes and that COX and LOX may play important roles in the oxidation of NNK in this organ. This suggestion appears to be further supported by observations made by Rioux and Castonguay (13) , who showed that inhibition of COX and LOX expression diminished NNK-induced lung tumorigenesis. COX also catalyzes conversion of certain polynuclear aromatic hydrocarbons and/or metabolites to the ultimate carcinogenic bay region diol epoxide (14 , 15) . Thus, it appears that COX and LOX enzyme systems are important in metabolic activation of carcinogens in extrahepatic tissues where P450 is not prevalent.

Two isoforms of COX, COX-1 and COX-2, have been identified (reviewed in Refs. 16 and 17 ). COX-1 is constitutively expressed in most tissues and is thought to be involved in maintaining cellular homeostasis. In contrast, COX-2 is frequently undetectable in nonneoplastic tissues, but it is inducible by phorbol esters, cytokines, growth factor, reactive oxygen species, and chemical carcinogens. For example, benzo[a]pyrene was found to up-regulate COX-2 gene expression in normal and transformed oral epithelial cells in vitro (18) . COX-2 but not COX-1 expression is markedly elevated in most colonic tumors in azoxymethane-treated rats and in intestinal neoplasia in Min mice (19 , 20) . In humans, overexpression of COX-2 has also been associated with colorectal cancer and lung cancers, specifically, adenocarcinomas (21, 22, 23) .

Epidemiological studies indicate that the fat content of the diet plays an important role in the risk for cancer of the lung (24 , 25) . Experimentally, the role of dietary fat and its relationship to carcinogenesis has been explored in various settings (26, 27, 28) . For example, the role of dietary fat in the development of NNK-induced adenoma, adenocarcinoma, and adenosquamous carcinoma in rat lung has been examined (28) ; the results underscore the likelihood of a dietary role of fat in human cancer that is suggested by epidemiological observations. Using archival rat lung neoplasms, we report here that NNK and HF diet increased COX-2 expression in progressively anaplastic pulmonary neoplasms. Also, COX-2 levels appear to rise early when NNK is given with a HF diet, which shortens the latency of lung tumor development in rats.


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results and Discussion
 REFERENCES
 
Source of Archival Lung Tumor.
Our bioassay has been described previously (28) . It consisted of the following groups: group 1, 23.5% corn oil (HF) diet, 2 ppm NNK, 60 rats (NNK-HF); group 2, 5% corn oil (LF) diet, 2 ppm NNK, 60 rats (NNK-LF); group 3, 23.5% corn oil diet, tap water, 20 rats (HF); group 4, 5% corn oil diet, tap water, 20 rats (LF). Groups 3 and 4 were negative controls. The NNK-containing drinking water was offered throughout the lives of the rats, beginning when they were 8 weeks of age. The animals were observed until they were moribund or until the scheduled termination of the experiment (when 90% of the rats in the longest surviving group had died), when the rats were killed by CO2 asphyxiation. Complete autopsies were performed, and H&E-stained microscopic slides were prepared for histopathological evaluation of all gross lesions in the lung.

Immunohistochemistry.
The immunohistochemistry method used was modified from a previously published study (29) . Four-µm-thick sections of formalin-fixed and paraffin-embedded tissue samples from gross lesions of the lung were microwaved in citrate buffer (pH 6), endogenous peroxidase was blocked with 3% hydrogen peroxide, and tissues were incubated with Universal Protein Blocker (Shandon Lipshaw, Pittsburgh, PA). Subsequently, tissues were incubated with primary antibody of prostaglandin H synthase 2 (COX-2), purchased from Caymen Chemical (Ann Arbor, MI). At a dilution of 1:50, the incubation was for 1 h at room temperature, followed by staining with biotinylated goat antirabbit Vector Elite Kit (Vector Laboratories, Burlingame, CA). Tissues were then incubated with strepavidin horseradish peroxidase enzyme (Lab Vision Corp., Fremont, CA) at room temperature for 20 min, followed by 3-amino-9-ethylcarbazole (AEC) chromogen for 7 min at room temperature.

Evaluation of COX-2 Immunostaining.
The intensity and extent of COX-2 positivity was graded in a blinded fashion with coding. Lung tissue samples showing undetectable or negligible expression of COX-2 were scored as grade 0. The intensity and degree of positive reaction were further scored as follows: grade 1, <30% positivity; grade 2, 30–60% positivity; grade 3, 60–90% positivity; and grade 4, >90% positivity. The scoring criteria were similar to those used with human specimens (21) .


   Results and Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results and Discussion
REFERENCES
 
COX-2 expression was examined in archival samples of lung neoplasms (adenomas, adenocarcinomas, and adenosquamous carcinomas) induced by NNK in male F344 rats fed either HF or LF diets (28) . The data presented in Table 1Citation summarize the total incidence of each tumor type and the mean grade (intensity/severity) of COX-2 expression, as assessed by immunohistochemistry for each tumor type. Furthermore, the latency (time to lethal tumor), expressed in weeks (mean ± SD), is also presented in Table 1Citation . The results reported here indicate for the first time that NNK causes increasingly higher levels of COX-2 expression with progressive stages of lung carcinogenesis in rats fed a HF diet and that COX-2 levels rise earlier, shortening tumor latency in rats maintained on NNK and HF diet compared to rats exposed to NNK and a LF regimen.


View this table:
[in this window]
[in a new window]

  		Table 1 Mean COX-2 expression over time in three types of lung neoplasia induced by NNK in male F344 rats

 
Morphologically, NNK-induced lung neoplasms were bronchoalveolar adenomas, bronchoalveolar carcinomas, and/or adenosquamous carcinomas. All of these neoplasms showed COX-2-positive expression in the interstitium, in the case of adenomas (Fig. 2, A and B)Citation ; within the cells of papillary growth in carcinomas (Fig. 2, C–F)Citation ; or even within squamous cell clusters in adenosquamous carcinomas (Fig. 2, G and H)Citation . The results presented in Table 1Citation reflect that, in group 1 (NNK plus HF diet), adenomas, adenocarcinomas, and adenosquamous carcinomas were of mean grades 2, 3, and 4, respectively. Group 2 (NNK plus LF) neoplasms were of mean grades 1, 1, and 3, respectively. Thus, in group 1, most adenomas were of grade 2 and most adenocarcinomas were of grade 3, whereas the corresponding neoplasms in group 2 were of grades 1 and 1, respectively.



View larger version (154K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. A, representative results of COX-2 immunostaining in NNK-induced bronchoalveolar adenoma in a rat of group 1 (NNK plus HF). COX-2-positive expression (diffuse brown discoloration) in the interstitium is evident. Magnification, x400. B, COX-2 immunostaining in NNK-induced bronchoalveolar adenoma of group 2 (NNK plus LF). COX-2-positive expression is evident in the interstitium. Magnification, x400. C, COX-2 immunostaining in NNK-induced bronchoalveolar carcinoma of group 1. COX-2-positive expression (diffuse brown discoloration) in the interstitium and within the cells of papillary growth is evident. Magnification, x400. D, COX-2 immunostaining in NNK-induced bronchoalveolar carcinoma of group 2. COX-2-positive expression is evident in the interstitium and within the cells of papillary growth. Magnification, x400. E, COX-2 immunostaining in NNK-induced bronchoalveolar carcinoma of group 1. COX-2-positive expression is evident in the interstitium and within the cells of papillary growth. Magnification, x400. F, COX-2 immunostaining in NNK-induced bronchoalveolar carcinoma of group 2. COX-2-positive expression is evident in the interstitium and within the cells of papillary growth. Magnification, x400. G, COX-2 immunostaining in NNK-induced adenosquamous anaplastic carcinoma of group 1. COX-2-positive expression is evident in the interstitium and within the cells of papillary growth and squamous cell clusters. Magnification, x400. H, COX-2 immunostaining in NNK-induced adenosquamous carcinoma of group 2. COX-2-positive expression is evident in the interstitium and within the cells of papillary growth and squamous cell clusters. Magnification, x400.

 
In the spontaneous lung neoplasms observed in control rats [groups 3 (HF) and 4 (LF)], the expression of COX-2 was either negligible (one adenoma of grade 0 in group 3) or of very low grade (one adenocarcinoma of grade 1 in group 4). Notably, nonneoplastic lung tissues had no measurable COX-2 expression. Conversely, in all NNK-induced lung neoplasms, there was an elevation in COX-2 expression that may be associated with the development of lung tumors induced by NNK in rats. Thus, these results, together with those reported previously on the increased expression of COX-2 in human lung cancer, suggest that the well-defined NNK lung tumor model assay will become valuable for studying pulmonary neoplasia using COX-2 as a marker. However, the dietary regimen (fat content of diet), both in model assays and in humans, appears to be most important.

Of particular significance is the latency of these neoplasms, i.e., the time to lethal tumor development for each specific type. The latency (in weeks) for lung adenomas (mean + SD) was 78.4 ± 10.9 in group 1, whereas the corresponding time in group 2 was 89.8 ± 5.6 (P < 0.05). In group 1, the adenomas were evident at ~11 weeks before the adenomas in group 2. For adenocarcinomas, the latency in group 1 (83.5 ± 8.7) was significantly different from that in group 2 (91.8 ± 7.8) at P < 0.01. The one adenosquamous carcinoma in group 1 was detected at 77 weeks, whereas the same type adenosquamous carcinoma in group 2 was detected at 92 weeks; again, 15 weeks after that in group 1. In the control groups, the adenoma was evident at 83 weeks [group 3 (NNK plus HF)] and the adenocarcinoma [group 4 (NNK plus LF)] at 96 weeks.

It is evident that inhibition of COXs retards tumorigenesis in animals, as was first demonstrated with nonsteroidal anti-inflammatory drugs, such as acetylsalicyclic acid (aspirin) and sulindac, which inhibit both COX activity and NNK-induced lung tumorigenesis in A/J mice (30) . It is worth noting that, in addition to the observation in A/J mice, an association between aspirin consumption and reduced lung cancer incidence in men was also reported (31) . Thus, it is essential to understand the mechanisms by which NNK or other carcinogens up-regulate COX-2 and how dietary fat modulates these effects, so that specific modes of intervention can be developed while critical signals that mediate the induction of COX-2 expression are monitored. Such investigations will be the focus of our future studies.


   ACKNOWLEDGMENTS
 
We thank Patricia Sellazzo for preparing and Ilse Hoffmann for editing this manuscript.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by the National Cancer Institute Grant CA-PO1-70972. This is American Health Foundation Paper No. 53 of the series "A Study of Tobacco Carcinogenesis." Back

2 To whom requests for reprints should be addressed, at American Health Foundation, 1 Dana Road, Valhalla, NY 10595. Back

3 The abbreviations used are: NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; COX, cyclooxygenase; LOX; lipooxygenase; HF, high-fat; LF, low-fat. Back

Received 12/ 9/98. Accepted 2/16/99.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results and Discussion
 REFERENCES
 

  1. IARC. . Tobacco Smoking: IARC Monograph on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, 38: IARC Lyon, France 1986.
  2. Wynder E. L., Hoffmann D. Smoking and lung cancer: scientific challenges and opportunities. Cancer Res., 54: 5284-5295, 1994.[Free Full Text]
  3. Thun M. J., Lilly C. A., Flannery J. T., Calle E. E., Flanders W. D., Heath C. W. Cigarette smoking and changes in the histopathology of lung cancer. J. Natl. Cancer Inst. (Bethesda), 89: 1580-1586, 1997.[Abstract/Free Full Text]
  4. Stellman S. D., Muscat J. E., Thompson S., Hoffmann D., Wynder E. L. Risk of squamous cell carcinoma and adenocarcinoma of the lung in relation to lifetime filter cigarette smoking. Cancer (Phila.), 50: 382-388, 1997.
  5. Wynder E. L. The past, present, and future of the prevention of lung cancer. Cancer Epidemiol. Biomark. Prev., 7: 735-748, 1998.[Abstract]
  6. Hoffmann D., Hoffmann I. The changing cigarette, 1950–1995. J. Toxicol. Environ. Health, 50: 307-364, 1997.[Medline]
  7. Hecht S. S., Hoffmann D. Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. Carcinogenesis (Lond.), 9: 875-884, 1988.[Free Full Text]
  8. Spiegelhalder B., Bartsch H. Tobacco-specific nitrosamines. Eur. J. Cancer Prev., 5: 33-38, 1996.
  9. Castonguay A., Stoner G. D., Schut H. A. J., Hecht S. S. Metabolism of tobacco-specific nitrosamines by cultured human tissues. Proc. Natl. Acad. Sci. USA, 80: 6694-6697, 1993.
  10. Hecht S. S. Biochemistry, biology and carcinogenicity of tobacco-specific N-nitrosamines. Chem. Res. Toxicol., 11: 559-603, 1998.[Medline]
  11. Hoffmann D., Brunnemann K. D., Prokopczyk B., Djordjevic M. V. Tobacco-specific N-nitrosamines, and areca-derived N-nitrosamines: chemistry, biochemistry, carcinogenicity, and relevance to humans. J. Toxicol. Environ. Health, 41: 1-52, 1994.[Medline]
  12. Smith T. J., Stoner G. D., Yang C. S. Activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in human lung microsomes by cytochromes P450, lipoxygenase, and hydroperoxides. Cancer Res., 55: 5566-5573, 1995.[Abstract/Free Full Text]
  13. Rioux N., Castonguay A. Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents. Carcinogenesis (Lond.), 19: 1393-1400, 1998.[Abstract/Free Full Text]
  14. Marnett L. J., Reed G. A., Dennison D. J. Prostaglandin synthetase-dependent activation of 7,8-dihydro-7,8-dihydroxy-benzo[a]pyrene to mutagenic derivatives. Biochem. Biophys. Res. Commun., 82: 210-216, 1978.[Medline]
  15. Eling T. E., Curtis J. F. Xenobiotic metabolism by prostaglandin H synthase. Pharmacol. Ther., 3: 261-273, 1992.
  16. Taketo M. M. Cyclooxygenase-2 inhibitors in tumorigenesis (Part I). J. Natl. Cancer Inst. (Bethesda), 90: 1529-1536, 1998.[Abstract/Free Full Text]
  17. Taketo M. M. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J. Natl. Cancer Inst. (Bethesda), 90: 1609-1620, 1998.[Abstract/Free Full Text]
  18. Kelly D. J., Mestre J. R., Subbaramaiah K., Sacks P. G., Schantz S. P., Tanabe T., Inoue H., Ramonetti J. T., Dannenberg A. J. Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells. Carcinogenesis (Lond.), 18: 795-799, 1997.[Abstract/Free Full Text]
  19. DuBois R. N., Radhika A., Reddy B. S., Entingh A. J. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology, 110: 1259-1262, 1996.[Medline]
  20. Williams C. S., Luongo C., Radhika A., Zhang T., Lamps L. W., Nanney L. B., Beauchamp R. D., DuBois R. N. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology, 111: 1134-1140, 1996.[Medline]
  21. Hida T., Yatabe Y., Achiwa H., Muramatsu H., Kozaki K-i., Nakamura S., Ogawa M., Mitsudomi T., Sugiura T., Takahashi T. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res., 58: 3761-3764, 1998.[Abstract/Free Full Text]
  22. Wolff H., Saukkonen K., Anttila S., Karjalainen A., Vainio H., Ristimäki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res., 58: 4997-5001, 1998.[Abstract/Free Full Text]
  23. Fujita T., Matsui M., Takaku K., Uetake H., Ichikawa W., Taketo M. M., Sugihara K. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res., 58: 4823-4826, 1998.[Abstract/Free Full Text]
  24. Wynder E. L., Hebert J. R., Kabat G. C. Association of dietary fat and lung cancer. J. Natl. Cancer Inst. (Bethesda), 79: 631-637, 1987.
  25. Goodman M. F., Hankin J. H., Wilkens L. R., Kolonel L. N. High-fat foods and the risk of lung cancer. Epidemiology, 3: 288-299, 1992.[Medline]
  26. Welsch C. W. Review of the effects of dietary fat on experimental mammary gland tumorigenesis: role of lipid peroxidation. Free Radical Biol. Med., 18: 757-773, 1995.[Medline]
  27. Reddy B. S. Animal experimental evidence on macronutrients and cancer Micozzi M. S. Moon T. E. eds. . Macronutrients, : 33-54, Dekker New York 1992.
  28. Hoffmann D., Rivenson A., Abbi R., Wynder E. L. A study of tobacco carcinogenesis: effect of the fat content of the diet on the carcinogenic activity of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in F344 rats. Cancer Res., 53: 2758-2761, 1993.[Abstract/Free Full Text]
  29. Wu K. K. Cyclooxygenase 2 induction: molecular mechanism and pathophysiologic rates. J. Lab. Clin. Med., 128: 242-245, 1996.[Medline]
  30. Duperron C., Castonguay A. Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. Carcinogenesis (Lond.), 18: 1001-1006, 1997.[Abstract/Free Full Text]
  31. Schreinemachers D. M., Everson R. B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology, 5: 138-146, 1994.[Medline]



This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
E. S. Park, I. G. Do, C. K. Park, W. K. Kang, J. H. Noh, T. S. Sohn, S. Kim, M.-J. Kim, and K.-M. Kim
Cyclooxygenase-2 Is an Independent Prognostic Factor in Gastric Carcinoma Patients Receiving Adjuvant Chemotherapy and Is Not Associated with EBV Infection
Clin. Cancer Res., January 1, 2009; 15(1): 291 - 298.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
S. I. Chang, K. El-Bayoumy, I. Sinha, N. Trushin, B. Stanley, B. Pittman, and B. Prokopczyk
4-(Methylnitrosamino)-I-(3-Pyridyl)-1-Butanone Enhances the Expression of Apolipoprotein A-I and Clara Cell 17-kDa Protein in the Lung Proteomes of Rats Fed a Corn Oil Diet but not a Fish Oil Diet
Cancer Epidemiol. Biomarkers Prev., February 1, 2007; 16(2): 228 - 235.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
S. Razani-Boroujerdi and M. L. Sopori
Early Manifestations of NNK-Induced Lung Cancer: Role of Lung Immunity in Tumor Susceptibility
Am. J. Respir. Cell Mol. Biol., January 1, 2007; 36(1): 13 - 19.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Ding, J. Li, C. Xue, K. Wu, W. Ouyang, D. Zhang, Y. Yan, and C. Huang
Cyclooxygenase-2 Induction by Arsenite Is through a Nuclear Factor of Activated T-cell-dependent Pathway and Plays an Antiapoptotic Role in Beas-2B Cells
J. Biol. Chem., August 25, 2006; 281(34): 24405 - 24413.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
C. A. Martey, S. J. Pollock, C. K. Turner, K. M. A. O'Reilly, C. J. Baglole, R. P. Phipps, and P. J. Sime
Cigarette smoke induces cyclooxygenase-2 and microsomal prostaglandin E2 synthase in human lung fibroblasts: implications for lung inflammation and cancer
Am J Physiol Lung Cell Mol Physiol, November 1, 2004; 287(5): L981 - L991.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
A. F. Gazdar, K. Miyajima, J. Reddy, U. G. Sathyanarayana, H. Shigematsu, M. Suzuki, T. Takahashi, and N. Shivapurkar
Molecular Targets for Cancer Therapy and Prevention
Chest, May 1, 2004; 125(5_suppl): 97S - 101S.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H.-Y. Lee, Y.-A. Suh, J. W. Kosmeder, J. M. Pezzuto, W. K. Hong, and J. M. Kurie
Deguelin-Induced Inhibition of Cyclooxygenase-2 Expression in Human Bronchial Epithelial Cells
Clin. Cancer Res., February 1, 2004; 10(3): 1074 - 1079.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. S. Carlton, R. Gopalakrishnan, A. Gupta, B. W. Liston, S. Habib, M. A. Morse, and G. D. Stoner
Piroxicam Is an Ineffective Inhibitor of N-Nitrosomethylbenzylamine-induced Tumorigenesis in the Rat Esophagus
Cancer Res., August 1, 2002; 62(15): 4376 - 4382.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. S. Hecht, S. G. Carmella, M. Ye, K.-a. Le, J. A. Jensen, C. L. Zimmerman, and D. K. Hatsukami
Quantitation of Metabolites of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone after Cessation of Smokeless Tobacco Use
Cancer Res., January 1, 2002; 62(1): 129 - 134.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Utsunomiya, M. Shimada, T. Rikimaru, K. Sugimachi, K.-I. Ohkura, S. Kaku, K. Yamada, and K.-I. Taguchi
Correspondence re: M. Kondo et al., Increased Expression of COX-2 in Nontumor Liver Tissue Is Associated with Shorter Disease-free Survival in Patients with Hepatocellular Carcinoma. Clin. Cancer Res., 5: 4005-4012, 1999.
Clin. Cancer Res., December 1, 2000; 6(12): 4965 - 4966.
[Abstract] [Full Text]

Home page
 CarcinogenesisHome page
N. Rioux and A. Castonguay
The induction of cyclooxygenase-1 by a tobacco carcinogen in U937 human macrophages is correlated to the activation of NF-{kappa}B
Carcinogenesis, September 1, 2000; 21(9): 1745 - 1751.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
A. K. Bauer, L. D. Dwyer-Nield, and A. M. Malkinson
High cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2) contents in mouse lung tumors
Carcinogenesis, April 1, 2000; 21(4): 543 - 550.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by El-Bayoumy, K.
Right arrow Articles by Wynder, E. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by El-Bayoumy, K.
Right arrow Articles by Wynder, E. L.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online